New Strategies in Lung Cancer: Epigenetic Therapy for Non-Small-Cell Lung Cancer|
The authors review the current status of attempts to target the epigenome, heritable modifications of DNA, histones and chromatin that may act to modulate gene expression independently of DNA coding alterations, in non-small-cell lung cancer and the potential for combinatorial and sequential treatment strategies. [Clin Cancer Res]
Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase III Study in Non-Small Cell Lung Cancer Misses First Co-Primary Endpoints|
Agenus Inc. announced that GlaxoSmithKline’s (GSK’s) MAGRIT study, a Phase III randomized, blinded, placebo-controlled MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon® adjuvant, did not meet its first or second co-primary endpoint. [Agenus Inc.]
VaxInnate Begins Phase I Clinical Trial to Evaluate Quadrivalent Vaccine for Prevention of Seasonal Flu
VaxInnate Corporation announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. [VaxInnate Corporation]
Ohio State Partners with MedVax Technologies, Inc. to Bring a Cancer Peptide Vaccine to Patients
The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking cancer peptide vaccine technologies. The anticancer vaccine technologies are designed for the treatment and prevention of cancers associated with the HER2 protein. [The Ohio State University]
From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.